SCHEMBL13606971

SCHEMBL13606971

CC1(C)OC2C(CO)OC(n3cnc(C(=N)N)n3)C2O1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNP P00491 4/20 0.63
▸ PI4KA P42356 1/20 0.49
▸ PI4K2B Q8TCG2 1/20 0.49
▸ PI4K2A Q9BTU6 1/20 0.49
▸ PI4KB Q9UBF8 1/20 0.49
▸ LMNA P02545 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ GLA P06280 1/20 0.48
▸ EIF4E P06730 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ TOP1 P11387 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ PMP22 Q01453 1/20 0.48
▸ TDP1 Q9NUW8 2/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762066 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL12892430 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL12879149 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL6839692 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL7377274 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL24024691 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL13058163 0.88 LMNA (0.63) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL13606967 0.85 PNP (0.48) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL6554011 0.82 LMNA (0.46) PNPPI4KAPI4K2BPI4K2API4KB
SCHEMBL13606972 0.81 PNP (0.49) PNPPI4KAPI4K2BPI4K2API4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638496-B2 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-12-29 — — US disclosed
US-7638496-B2 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-12-29 — — US disclosed
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 — — US disclosed
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2009-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176721-A1 NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE NT5C2, PNP, SLC29A1 PNP 2/4885PI4KA 1182/4885PI4K2B 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback